Aptose Biosciences Inc (APTO) - News Archive

Aptose Biosciences Inc. a clinical-stage biotechnology company known for its innovative approaches to cancer therapy, recently announced two significant financial maneuvers designed to strengthen its operational foundat...

In the dynamic field of cancer research, Aptose Biosciences Inc. is making significant strides with its promising therapeutic candidate, Tuspetinib. Recently, the company announced a series of findings that underline th...

In a groundbreaking development for the treatment of acute myeloid leukemia (AML), Aptose Therapeutics, a leader in oncology innovation, has announced the initiation of the TUSCANY Phase 1/2 study. This pioneering clini...

In an era where innovation meets urgency, Aptose Biosciences Inc. is making notable strides in the treatment landscape for newly diagnosed acute myeloid leukemia (AML). In the recently released third quarter results for...

: This article outlines the recent financial facilitation between Aptose Biosciences Inc. and Hanmi Pharmaceutical Co. Ltd. alongside ongoing discussions about a prospective joint development effort focused on Tuspetini...

Aptose Biosciences Receives Deficiency Notice from Nasdaq, Impacting Share PriceAptose Biosciences Inc., a clinical-stage precision oncology company, recently announced that it has received a deficiency letter from Nasd...

The European Hematology Association (EHA) 2024 Hybrid Congress witnessed a groundbreaking revelation in the field of hematological research, as Aptose Biosciences presented remarkable clinical and preclinical findings f...

Aptose Announces Successful Closure of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Following Remarkable Financial PerformanceIn a recent press release, Aptose Biosciences Inc. ( Apto...

In recent news, Aptose Biosciences Inc, a leading biopharmaceutical company, has announced a registered direct offering priced at-the-market under Nasdaq rules, raising $4.43 million. This development comes amidst a dec...

Aptose Therapeutics Forges Strategic Partnership with Hanmi Pharmaceutical Alongside Successful Public Offering and Private PlacementIn a significant move towards fortifying its position in the oncology market, Canadian...

In a momentous breakthrough in the field of leukemia treatment, Aptose Biosciences experimental drug Tuspetinib (TUS) has exhibited remarkable effectiveness in an ongoing Phase 1/2 study for patients with relapsed or re...